Aerie Pharmaceuticals (Aerie Pharmaceuticals) Insider Ownership : 3.13 % (As of May. 06, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aerie Pharmaceuticals's insider ownership is 3.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aerie Pharmaceuticals's Institutional Ownership is 51.96%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aerie Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 98.23%.

Aerie Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Aerie Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Insider Ownership Chart

Aerie Pharmaceuticals Historical Data

The historical data trend for Aerie Pharmaceuticals can be seen below:

	2022-01-31	2022-02-28	2022-03-31	2022-04-30	2022-05-31	2022-06-30	2022-07-31	2022-08-31	2022-09-30	2022-10-31
Insider Ownership	3.04	2.92	3.10	3.08	3.08	3.16	3.18	3.13	3.13	3.13

Aerie Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703

Website

https://www.aeriepharma.com

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Executives

Peter Frederick Lang	officer: Chief Financial Officer	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese	officer: Vice President of Finance	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley	officer: CHRO & VP, Corp Services	15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten	officer: Interim CFO	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski	officer: Chief Scientific Officer	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell	director	2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander	officer: Chief R&D Officer	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino	officer: Chief Financial Officer
Vicente Jr Anido	director, officer: Chief Executive Officer	1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro	officer: President and COO	15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618